ChromaDex achieves second NDI for higher dose Niagen

The second notification was for 300mg per day. The ingredient also has a letter of no objection form the FDA​ for the Generally Recognized as Safe (GRAS) status, allowing the ingredient to be used in vitamin waters, protein shakes, nutrition bars, gum and chews.

“We are pleased to offer Tru Niagen users a 300mg daily serving of our revolutionary ingredient,”​ says Robert Fried, ChromaDex CEO. “This will provide an extra boost in NAD levels, which decline with age and the daily stressors of life.”​

Niagen​

Nicotinamide riboside (NR) is found naturally in trace amounts in milk and other foods, and is a more potent, no-flush version of niacin (vitamin B3). Published research has shown that NR is a potent precursor to NAD+ in the mitochondria of animals. NAD+ is an important cellular co-factor for improvement of mitochondrial performance and energy metabolism.

As organisms age, NAD+ levels drop, which leads to a decrease in mitochondrial health; this in turn leads to age-related health issues.  Low NAD+ levels limit activity of a group of enzymes called sirtuins, which are believed to play a key role in longevity. NAD+ levels also can be depleted by lifestyle choices such as overeating and lack of exercise. By boosting NAD+, NR may increase mitochondrial health and induce the creation of new mitochondria.

Irvine, CA-based Chromadex has been accumulating the IP surrounding NR for a couple of years, having licensed patents from Cornell University, Dartmouth College, and Washington University in St Louis.

Niagen was clinically-studied at 300mg to increase NAD in 2016​, published in the journal Nature Communications​. Since then, three additional clinical studies have published on Niagen.